microRNA在肝细胞癌有氧糖酵解中的调控作用

牛亚倩; 常钰玲; 刘芳; 赵川; 陈彻

doi:10.3969/j.issn.1001-5256.2019.09.044

microRNA在肝细胞癌有氧糖酵解中的调控作用

DOI: 10.3969/j.issn.1001-5256.2019.09.044

甘肃中医药大学

基金项目:

国家自然科学基金资助项目(81460456)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1033
- HTML全文浏览量: 63
- PDF下载量: 240
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-20
- 出版日期: 2019-09-20

Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma

Gansu University of Chinese Medicine

Research funding:

摘要

摘要: 葡萄糖代谢重组是肝细胞癌(HCC)一个重要标志,癌细胞能迅速地将其能量来源从线粒体氧化磷酸化调整到糖酵解代谢,满足其在低氧环境下的高效增殖。近年来,越来越多的证据表明,microRNA(miRNA)的转录后调控在精细调节代谢重编程发挥关键作用,与HCC的临床病理特征及发生发展密切相关。影响糖酵解的因素有很多,系统的总结了miRNA在HCC中异常表达对有氧糖酵解的直接和间接调控的作用,为HCC的早期诊断、靶向治疗及预后检测提供理论依据。
- 癌,肝细胞 /
- 微RNAs /
- 糖酵解
Abstract: Glucose metabolism recombination is an important marker of hepatocellular carcinoma ( HCC) , and cancer cells can quickly adjust their energy sources from mitochondrial oxidative phosphorylation to glycolysis to meet the need of efficient proliferation in the hypoxic environment. In recent years, more and more studies have shown that post-transcriptional regulation of microRNAs ( miRNAs) plays a key role in the fine regulation of metabolic reprogramming, which is closely associated with the clinicopathological features, development, and progression of HCC. There are various influencing factors for glycolysis, and therefore, this article reviews the influence of abnormal expression of miRNAs on the direct and indirect regulation of aerobic glycolysis in HCC, in order to provide a theoretical basis for the early diagnosis, targeted treatment, and prognostic evaluation of HCC.
- carcinoma, hepatocellular /
- microRNAs /
- glycolysis

HTML全文

参考文献(31)

[1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136 (5) :e359-e386.

[2] ZHANG H, ZHANG H, LIU L, et al. An excerpt of AASLD guidelines for the treatment of hepatocellular carcinoma (2018) [J]. J Clin Hepatol, 2018, 34 (4) :743-748. (in Chinese) 张宏, 张浩, 琉璃.《2018年美国肝病学会肝细胞癌治疗指南》摘译[J].临床肝胆病杂志, 2018, 34 (4) :743-748.

[3] GILLIES RJ, GATENBY RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis[J]. Cancer Metastasis Rev, 2007, 26 (2) :311-317.

[4] SADRI NAHAND J, BOKHARAEI-SALIM F, SALMANINEJAD A, et al. microRNAs:Key players in virus-associated hepatocellular carcinoma[J]. J Cell Physiol, 2018, 234 (8) :12188-12225.

[5] SWITLIK WZ, BIELECKA-KOWALSKA A, KARBOWNIK MS, et al. Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma:A preliminary study[J].Biomark Med, 2019, 13 (7) :523-534.

[6] ZHOU W, YANG WL, ZHANG HW, et al. Advances in the relationship between microRNA-483 and digestive system tumors[J]. Chin J Dig Surg, 2018, 17 (5) :522-526. (in Chinese) 周威, 杨万里, 张洪伟, 等.微RNA-483与消化系统肿瘤关系的研究进展[J].中华消化外科杂志, 2018, 17 (5) :522-526.

[7] BENJAMIN DI, CRAVATT BF, NOMURA DK. Global profiling strategies for mapping dysregulated metabolic pathways in cancer[J]. Cell Metab, 2012, 16 (5) :565-577.

[8] ORANG AV, PETERSEN J, MCKINNON RA, et al. Micromanaging aerobic respiration and glycolysis in cancer cells[J]. Mol Metab, 2019, 23:98-126.

[9] JAFARY F, GANJALIKHANY MR, MORADI A, et al. Novel peptide inhibitors for lactate dehydrogenase A (LDHA) :A survey to inhibit LDHA activity via disruption of protein-protein interaction[J]. Sci Rep, 2019, 9 (1) :4686.

[10] FU Y, SUN LQ, HUANG Y, et al. miR-142-3p inhibits the metastasis of hepatocellular carcinoma cells by regulating HMGB1 gene expression[J]. Curr Mol Med, 2018, 18 (3) :135-141.

[11] HUA S, LIU C, LIU L, et al. miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA[J]. Biochem Biophys Res Commun, 2018, 496 (3) :947-954.

[12] IANSANTE V, CHOY PM, FUNG SW, et al. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation[J].Nat Commun, 2015, 6:7882.

[13] ZHAO R, LI L, YANG J, et al. Overexpression of pyruvate kinase M2 in tumor tissues is associated with poor prognosis in patients with hepatocellular carcinoma[J]. Pathol Oncol Res, 2019.[Epub ahead of print]

[14] CAO F, YIN LX. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/beta-catenin pathway[J]. Exp Mol Pathol, 2019, 106:34-43.

[15] TSAI WC, HSU SD, HSU CS, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis[J].J Clin Invest, 2012, 122 (8) :2884-2897.

[16] VALDMANIS PN, KIM HK, CHU K, et al. miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression[J]. Nat Commun, 2018, 9 (1) :5321.

[17] LIU AM, XU Z, SHEK FH, et al. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma[J]. PLo S One, 2014, 9 (1) :e86872.

[18] DEWAAL D, NOGUEIRA V, TERRY AR, et al. Hexokinase-2depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J]. Nat Commun, 2018, 9 (1) :446.

[19] GUO W, QIU Z, WANG Z, et al. MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer[J].Hepatology, 2015, 62 (4) :1132-1144.

[20] ZHANG LF, LOU JT, LU MH, et al. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma[J]. EMBO J, 2015, 34 (21) :2671-2685.

[21] KULSHRESHTHA R, FERRACIN M, WOJCIK SE, et al. A microRNA signature of hypoxia[J]. Mol Cell Biol, 2007, 27 (5) :1859-1867.

[22] MAHON PC, HIROTA K, SEMENZA GL. FIH-1:A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity[J]. Genes Dev, 2001, 15 (20) :2675-2686.

[23] CHEN Z, ZUO X, ZHANG Y, et al. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1alphamediated Warburg effect[J]. Cell Death Dis, 9 (5) :549.

[24] JIANG W, ZHANG L, GUO Q, et al. Identification of the pathogenic biomarkers for hepatocellular carcinoma based on RNAseq analyses[J]. Pathol Oncol Res, 2019, 25 (3) :1207-1213.

[25] LI B, HE L, ZUO D, et al. Mutual regulation of MiR-199a-5p and HIF-1alpha modulates the Warburg Effect in hepatocellular carcinoma[J]. J Cancer, 2017, 8 (6) :940-949.

[26] LI W, WANG J, CHEN QD, et al. Insulin promotes glucose consumption via regulation of miR-99a/m TOR/PKM2 pathway[J]. PLo S One, 2013, 8 (6) :e64924.

[27] YU XN, CHEN H, LIU TT, et al. Targeting the m TOR regulatory network in hepatocellular carcinoma:Are we making headway?[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871 (2) :379-391.

[28] JIA YY, ZHAO JY, LI BL, et al. miR-592/WSB1/HIF-1alpha axis inhibits glycolytic metabolism to decrease hepatocellular carcinoma growth[J]. Oncotarget, 2016, 7 (23) :35257-35269.

[29] BIE CQ, LIU XY, CAO MR, et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression[J]. Oncotarget, 2016, 7 (48) :79305-79318.

[30] GAO Y, ZHANG SG, WANG ZH, et al. Down-regulation of miR-342-3p in hepatocellular carcinoma tissues and its prognostic significance[J]. Eur Rev Med Pharmacol Sci, 2017, 21 (9) :2098-20102.

[31] LIU W, KANG L, HAN J, et al. miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect[J]. Onco Targets Ther, 2018, 11:1643-1653.

施引文献

资源附件(0)

访问统计